Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 85

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 85
---
 market price at the Closing; and (2) will enter into indemnification agreements between NLS and members of the board of directors. Additionally, Prof. Michel Revel, MD, Director and Chief Scientific Officer of Kadimastem and the beneficial owner of 1,321,109shares of Kadimastem as of June 20, 2025, and Ronen Twito, Executive Chairman and CEO of Kadimastem, and beneficial owner of 367,332shares of Kadimastem as of June 20, 2025, will benefit directly from the exchange of their shares of Kadimastem in exchange for shares of NLS resulting from the Merger. Treatment of Kadimastem and Kadimastem’s Equity Awards and Award Plan (Page 142) At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement. For more information please see “ The Merger Agreement — Equity Awards and Warrants” of this proxy statement/prospectus. 14 No Solicitation of Acquisition Proposals (Page 144) NLS also agreed during the period between the signing of the Merger Agreement and the earlier of the Closing or the termination of the Merger Agreement in accordance with its terms, or the Interim Period, not to solicit or enter into any inquiry, proposal or offer, or any indication of interest in making an offer or proposal for an alternative competing transactions, to notify Kadimastem as promptly as practicable in writing of the receipt of any inquiries, proposals or offers, requests for information or requests relating to an alternative competing transaction or any requests for non -publicinformation relating to such transaction, and to keep Kadimastem informed of the status of any such inquiries, proposals, offers or requests for information. If the NLS Board determines, after consultation with its financial advisors and outside legal counsel, that an unsolicited Parent Acquisition Proposal constitutes a Parent Superior Proposal it may, subject to giving Kadimastem an opportunity to propose revisions to the Merger Agreement which would cause such Parent Superior Proposal to no longer constitute a Parent Superior Proposal, cause NLS to terminate the Merger Agreement in order to enter into a definitive agreement relating to such Parent Superior Proposal and